Web Results

en.wikipedia.org/wiki/Fulvestrant

Fulvestrant, sold under the trade name Faslodex among others, is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in ...

medlineplus.gov/druginfo/meds/a607031.html

Nov 15, 2016 ... Fulvestrant Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus.

chemocare.com/chemotherapy/drug-info/fulvestrant.aspx

Fulvestrant (Faslodex) estrogen receptor downregulator hormone therapy side effects, how it's given, how it works, precautions and self care tips for treatment of  ...

www.cancer.gov/about-cancer/treatment/drugs/fulvestrant

Oct 5, 2006 ... This page contains brief information about fulvestrant and a collection of links to more information about the use of this drug, research results, ...

www.faslodex.com

Official patient site for FASLODEX® (fulvestrant) Injection 500 mg, a treatment option for postmenopausal women with hormone receptor-positive metastatic ...

pubchem.ncbi.nlm.nih.gov/compound/Fulvestrant

Fulvestrant is a steroidal antiestrogen that is used in the treatment of hormone- receptor positive metastatic breast cancer. Fulvestrant therapy can be associated  ...

www.ncbi.nlm.nih.gov/pubmed/15018596

Fulvestrant (Faslodex) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen.

www.faslodexhcp.com/fulvestrant-dosing.html

FASLODEX® (fulvestrant) Injection 500 mg Dosing. Consistent regimen: FASLODEX is given as the same dose (500 mg) whether it's used as monotherapy or in ...

www.rxlist.com/faslodex-drug.htm

FASLODEX® (fulvestrant) injection for intramuscular administration is an estrogen receptor antagonist. The chemical name is 7-alpha-[9-(4,4,5,5,5-penta ...

www.astrazeneca-us.com/media/press-releases/2016/fda-approves-new-indication-for-faslodex-fulvestrant-20160302.html

FDA approves new indication for FASLODEX® (fulvestrant). PUBLISHED 2 March 2016. Wednesday, 2 March 2016. Approval expands use and offers additional ...